Stockscreener 앱 받기
4.32
1.14%
-0.05
전일 마감가:
$4.37
열려 있는:
$4.39
하루 거래량:
1.11M
Relative Volume:
0.80
시가총액:
$603.35M
수익:
$8.37M
순이익/손실:
$-69.66M
주가수익비율:
-7.7088
EPS:
-0.5604
순현금흐름:
$-51.45M
1주 성능:
-0.92%
1개월 성능:
-11.48%
6개월 성능:
+32.92%
1년 성능:
+182.35%
1일 변동 폭
$4.29
$4.5287
1주일 범위
$4.0742
$4.5287
52주 변동 폭
$1.3426
$5.15
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.32 | 603.35M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Oppenheimer | Outperform |
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com
Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan
Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan
Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Stockholders Approve Directors, Pay and Auditor - TipRanks
Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Aclaris Therapeutics (ACRS) Edges Higher, Testing Key Resistance Near $4.81High Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Edges Higher, Testing Resistance After Modest UptickGrowth ETF - The Legal Advocate
Aclaris Therapeutics Holds Steady Near Mid-Range as Traders Eye Key Support and ResistanceVolume Climax - thelegaladvocate.com
Aclaris Therapeutics (ACRS) Edges Lower Amid Tight Trading RangeHigh Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Holds Near Support as Volume Suggests Cautious SentimentCTA Positioning - The Legal Advocate
Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView
926-share sale notice for Aclaris Therapeutics (NASDAQ: ACLS) via Form 144 - Stock Titan
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo
ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView
ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView
Aclaris (ACRS) Crushes Q1 2026 Estimates — EPS $-0.15 Tops ViewsSurprise Factor Analysis - newsline.com
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
MSN Money - MSN
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria
Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times
Aclaris: Q1 Earnings Snapshot - theheraldreview.com
The market share dynamics in Aclaris (ACRS) results | Q4 2025: Below ExpectationsEarnings Growth Analysis - newsline.com
Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan
Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo
Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan
Aclaris says cash lasts through 2028 with key skin, asthma data due - Stock Titan
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):